Investigated for treating COVID-19.
Contra-indicated in patients with active pathological bleeding.
- TRADE NAME: Xarelto (Janssen)
- INDICATIONS: Prevention of venous thromboembolism in patients undergoing knee or hip replacement surgery; treatment of deep vein thrombosis and pulmonary embolism
- CLASS: Anticoagulant (antithrombotic), Direct factor Xa inhibitor
- HALF-LIFE: 5–9 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Anticoagulants, Aspirin, Atazanavir, Atorvastatin, Carbamazepine, Clarithromycin, Clopidogrel, Combined P-glycoprotein and strong CYP3A4 inhibitors and inducers, Conivaptan, Dabigatran, Darunavir, Delavirdine, Diclofenac, Efavirenz, Enoxaparin, Erythromycin, Fosamprenavir, HIV protease inhibitors, Indinavir, Itraconazole, Ketoconazole, Ketorolac, Lapatinib, Lopinavir, Nelfinavir, Phenobarbital, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Tipranavir, Voriconazole
- See adverse reactions attributed to class:
PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS and SPINAL/EPIDURAL HEMATOMA
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 12/19/2025
